endpts.com·May 19, 2026
Relay Therapeutics reported positive Phase 2 data for zovegalisib, a PI3Kα inhibitor, in a rare genetic disease, surpassing Wall Street expectations and broadening its research and development potential beyond breast cancer.
Relay Therapeutics' successful Phase 2 data readout for zovegalisib in a rare genetic disease highlights the potential to expand the use of their PI3Kα inhibitor beyond breast cancer, signaling a promising R&D opportunity for investors and stakeholders in biotech focused on precision medicine and rare diseases.